These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2150739)

  • 1. Osmolality and pH of anti-asthmatic drug solutions.
    Desager KN; Van Bever HP; Stevens WJ
    Agents Actions; 1990 Nov; 31(3-4):225-8. PubMed ID: 2150739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Osmolarity of solutions used in nebulization].
    Portel L; Tunon de Lara JM; Vernejoux JM; Weiss I; Taytard A
    Rev Mal Respir; 1998 Apr; 15(2):191-5. PubMed ID: 9608990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osmolality changes in nebulizer solutions.
    Schöni MH; Kraemer R
    Eur Respir J; 1989 Oct; 2(9):887-92. PubMed ID: 2572453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
    Akapo S; Gupta J; Martinez E; McCrea C; Ye L; Roach M
    Ann Pharmacother; 2008 Oct; 42(10):1416-24. PubMed ID: 18780805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical compatibility of fluticasone-17- propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions.
    Kamin W; Schwabe A; Krämer I
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):599-607. PubMed ID: 18268934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compatibility of nebulizer solution admixtures.
    Joseph JC
    Ann Pharmacother; 1997 Apr; 31(4):487-9. PubMed ID: 9101012
    [No Abstract]   [Full Text] [Related]  

  • 7. Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium.
    Lee TY; Chen CM; Lee CN; Chiang YC; Chen HY
    Am J Health Syst Pharm; 2005 Apr; 62(8):828-33. PubMed ID: 15821276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative therapeutic effect of bronchodilator aerosols and salbutamol cyclocaps].
    Ninković M; Bjelajac D; Ranković B; Dangubić V; Plavec G
    Vojnosanit Pregl; 1993; 50(6):589-92. PubMed ID: 8197732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol.
    Krämer I; Schwabe A; Lichtinghagen R; Kamin W
    Pharmazie; 2007 Oct; 62(10):760-6. PubMed ID: 18236781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the physical-chemical compatibility of cromolyn sodium nebulizer solution: bronchodilator inhalant solution admixtures.
    Emm T; Metcalf JE; Lesko LJ; Chai MF
    Ann Allergy; 1991 Feb; 66(2):185-9. PubMed ID: 1899784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
    Kamin W; Schwabe A; Krämer I
    J Cyst Fibros; 2006 Dec; 5(4):205-13. PubMed ID: 16678502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The function profile of compressed-air and ultrasonic nebulizers.
    Wu HL; Lin YZ; Wu WF; Huang FY
    Acta Paediatr Taiwan; 2003; 44(5):264-8. PubMed ID: 14964980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma.
    Watson WT; Becker AB; Simons FE
    J Allergy Clin Immunol; 1988 Dec; 82(6):1012-8. PubMed ID: 2974463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in osmolarity of disodium cromoglycate solution and protection against exercise-induced bronchospasm in children with asthma.
    Kano S; Hirose T; Nishima S
    Eur Respir J; 1996 Sep; 9(9):1891-5. PubMed ID: 8880108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition.
    Johnson MA; Newman SP; Bloom R; Talaee N; Clarke SW
    Chest; 1989 Jul; 96(1):6-10. PubMed ID: 2525460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma.
    Bryant DH; Rogers P
    Chest; 1992 Sep; 102(3):742-7. PubMed ID: 1387604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of conventional and ultrasonic nebulisation of bronchodilator drugs in asthmatic subjects.
    Sears MR
    N Z Med J; 1983 Nov; 96(743 Pt 2):927-9. PubMed ID: 6226884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma.
    Maesen FP; Greefhorst LP; Smeets JJ; Wald FD; Cornelissen PJ
    Respiration; 1997; 64(4):273-80. PubMed ID: 9257362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a stability-indicating high-performance liquid chromatography method for the simultaneous determination of albuterol, budesonide, and ipratropium bromide in compounded nebulizer solutions.
    Blewett AJ; Varma D; Gilles T; Butcher R; Jacob J; Amazan J; Jansen SA
    J AOAC Int; 2011; 94(1):110-7. PubMed ID: 21391487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disodium cromoglycate use in children and adolescents with asthma: correlation between plasma concentrations and protective effects for various inhalation methods.
    Kato Y; Muraki K; Fujitaka M; Sakura N; Ueda K
    Ann Allergy Asthma Immunol; 1999 Dec; 83(6 Pt 1):553-8. PubMed ID: 10619349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.